GNAS and central nervous system cancer: None of the twelve tumors (7 gliomas, 3 supratentorial PNETs, 2 ependymomas) tested with IHC displayed any NESP55 immunoreactivity in regions with hypoxia-induced VEGFA expression, or elsewhere in the tumors.